Adjusted indirect comparison of intracoronary drug-eluting stents: evidence from a metaanalysis of randomized bare-metal-stent-controlled trials
International Journal of CardiologyPublished 19 December 2004
Giuseppe Biondi‐Zoccai, Pierfrancesco Agostoni, Antonio Abbate, Luca Testa, Francesco Burzotta, Marzia Lotrionte
Citations65
SJR quartileQ1
SJR score1.13
SNIP0.96
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
The present metaanalysis confirms the effectiveness of both Cypher and Taxus, supports the promising role of everolimus-eluting stents, and suggests the significant inferiority of most other devices.
Abstract
Notwithstanding its inherent limitations, the present metaanalysis confirms the effectiveness of both Cypher and Taxus, supports the promising role of everolimus-eluting stents, and suggests the significant inferiority of most other devices. These post hoc findings, albeit intriguing, await prospective confirmation.
Keywords
Medicine
New England Journal of MedicineA Randomized Comparison of a Sirolimus-Eluting Stent with a Standard Stent for Coronary Revascularization
4,031 Citations2002Marie‐Claude Morice, Patrick W. Serruys +10 more
As compared with a standard coronary stent, a sirolimus-eluting stent shows considerable promise for the prevention of neointimal proliferation, restenosis, and associated clinical events.
Journal of Clinical EpidemiologyThe results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials
2,002 Citations1997Heiner C. Bucher, Gordon Guyatt +2 more
An alternative model is presented that evaluates the differences between treatment and placebo in two sets of clinical trials, and preserves the randomization of the originally assigned patient groups.
CirculationRandomized Study to Assess the Effectiveness of Slow- and Moderate-Release Polymer-Based Paclitaxel-Eluting Stents for Coronary Artery Lesions
1,017 Citations2003Antonio Colombo, J Drzewiecki +10 more
Compared with a bare metal stent, paclitaxel-eluting stents reduced in-stent neointimal formation and restenosis and improved 12-month clinical outcome of patients with single de novo coronary lesions.
The LancetSirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS)
955 Citations2003Joachim Schofer, Michael Schlüter +5 more
Sirolimus-eluting stents are better than bare-metal stents for treatment of single long atherosclerotic lesions in a coronary vessel smaller than 3 mm in diameter.
BMJValidity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses
946 Citations2003Fujian Song, Douglas G Altman +2 more
Results of adjusted indirect comparison usually, but not always, agree with those of head to head randomised trials The validity ofadjusted indirect comparisons depends on the internal validity and similarity of the trials involved.
CirculationTAXUS I
868 Citations2003Eberhard Grube, Sigmund Silber +5 more
In this feasibility trial, the TAXUS slow-release stent was well tolerated and showed promise for treatment of coronary lesions, with significant reductions in angiographic and intravascular ultrasound measures of restenosis.
CirculationOne-Year Clinical Results With the Slow-Release, Polymer-Based, Paclitaxel-Eluting TAXUS Stent
763 Citations2004Gregg W. Stone, Stephen G. Ellis +10 more
The relative efficacy reported at 9 months for the polymer-based, paclitaxel-eluting TAXUS stent compared with the EXPRESS stent is preserved and continues to increase at 1 year, with no safety concerns apparent.
Journal of the American College of CardiologyThe Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS)
579 Citations2004Érick Schampaert, Eric A. Cohen +6 more
In patients with long lesions in small vessels, the SES dramatically reduces the risk of restenosis at eight months, translating into an excellent clinical outcome at nine months.
CirculationAnalysis of 1-Year Clinical Outcomes in the SIRIUS Trial
516 Citations2004David R. Holmes, Martin B. Leon +10 more
Placement of the sirolimus-eluting stent results in continued clinical improvement at 1 year after initial implantation, with significant reduction in clinical restenosis as defined by target-lesion revascularization.
New England Journal of MedicineA Paclitaxel-Eluting Stent for the Prevention of Coronary Restenosis
455 Citations2003Seung‐Jung Park, Won Heum Shim +10 more
Paclitaxel-eluting stents used with conventional antiplatelet therapy effectively inhibit restenosis and neointimal hyperplasia, with a safety profile similar to that of standard stents.
CirculationInhibition of Restenosis With a Paclitaxel-Eluting, Polymer-Free Coronary Stent
239 Citations2004Anthony Gershlick, Ivan De Scheerder +11 more
Paclitaxel applied directly to the abluminal surface of a bare metal coronary stent, at a dose density of 2.7 &mgr;g/mm2, reduced angiographic indicators of in-stent restenosis without short- or medium-term side effects.
CirculationNon–Polymer-Based Paclitaxel-Coated Coronary Stents for the Treatment of Patients With De Novo Coronary Lesions
202 Citations2004Alexandra J. Lansky, Ricardo A. Costa +19 more
The ACHIEVE paclitaxel-coated stent decreased neointimal proliferation compared with the bare-metal PENTA stent; however, this reduction was insufficient to meet the prespecified primary end point of target-vessel failure and the secondary end pointof binary restenosis.
CirculationSix- and Twelve-Month Results From First Human Experience Using Everolimus-Eluting Stents With Bioabsorbable Polymer
191 Citations2004Eberhard Grube, Shinjo Sonoda +7 more
In this initial clinical experience, EES with bioabsorbable polymer demonstrated a safe and efficacious method to reduce in-stent neointimal hyperplasia and restenosis.
European Heart JournalDrug-eluting stents: an early systematic review to inform policy*1, *2
136 Citations2004Ruaraidh Hill
The early data available indicate that DES reduce adverse cardiac events, mainly revascularisations, however, these data are limited in terms of patient numbers, length of follow-up, and method of outcome assessment.
Journal of the American College of Cardiology1139-61 Is the sirolimus drug eluting stent better than paclitaxel coated stent in “real life” environment?
2 Citations2004Jean-Christophe E Stauffer, Charles Seydoux +1 more
There was no significant difference in the incidence of MACE between sirolimus and paclitaxel group during this short follow-up, and clinical outcome (MACE incidence at 9 months) is the primary end-point.